A recent retrospective cohort study has highlighted concerns regarding the efficacy and safety of botulinum toxin type A (BTA) injections following COVID-19 vaccination.
The study involved 45 patients who underwent periodic BTA treatments who had completed two doses of Pfizer-BioNTech vaccine. All patients were injected with BTA in the frontalis muscle, glabella and lateral periorbital bilaterally to correct forehead and crow’s feet wrinkles by the same physician. The same units were injected for the same area before and after the vaccine.
The mean interval between BTA injections before completing COVID-19 vaccination was estimated at 118.64 days, whereas the same interval after getting vaccinated was 95.95 days. Therefore, the average interval between BTA injections was significantly shorter after getting vaccinated as compared to the interval prior to the beginning of the vaccination campaign.
None of the injected patients developed swelling, erythema or flu-like symptoms after BTA injections following COVID-19 vaccine. The number of patients who needed correction two weeks after BTA injection was 5% and 30% pre- and post-COVID-19 vaccines.
The current study provided an insight into the fact that the vaccine might confer reduced effectiveness of BTA. Further research is warranted and studies originating from ethnic populations are critical to reproduce findings.